Biologics reduce severe asthma exacerbation rates in meta-analysis of 6 RCTs and a case-seriesBiologics Show Significant Reduction in Severe Asthma Exacerbation Rates

The European respiratory journal Published October 24, 2026 Study authors: Boakye-Dankwa Ernest, Kiddle Steven J, Koo Hyewon Nina, Harper Andrew R, Ambrose Christopher S, Doug… PubMed ↗ NCT03373045 ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that biologics significantly reduce severe asthma exacerbation rates in both clinical trials and real-world settings.

This meta-analysis synthesizes data from 6 randomized controlled trials and one self-controlled case-series to evaluate the efficacy of biologics in adults with severe asthma. The study focuses on exacerbation rates as the primary outcome, comparing a biologic-exposed period to an unexposed period.

The meta-analysis of RCTs reported a rate ratio of 0.53 (95% CI 0.47-0.60) for reduced exacerbation rates. The real-world self-controlled case-series showed a further reduction with an IRR of 0.43 (95% CI 0.39-0.48). Several factors were identified as significant effect modifiers, including smoking history (ratio of ratios 0.50), exacerbation history (ratio of ratios 0.49), exhaled nitric oxide fraction (ratio of ratios 0.63), and blood eosinophil count (ratio of ratios 0.65).

Authors noted that spirometry-based exclusions may limit the generalizability of the findings. Clinical relevance is noted for patients with elevated type 2 biomarkers, minimal smoking, and a history of exacerbations, as these factors may identify the population most likely to benefit from biologic therapy. No data regarding adverse events or tolerability were reported.

How this fits prior evidence

This meta-analysis provides evidence for the efficacy of biologics in severe asthma, expanding upon the biological basis of asthma endotypes previously noted. While the prior coverage on the AEC-macrophage axis established a basis for targeting specific asthma endotypes, this study quantifies the impact of biologics on exacerbation rates. It also reinforces the clinical relevance of specific biomarkers like eosinophil counts and exhaled nitric oxide in identifying patients who may benefit from these interventions.

A large review of clinical trials and real-world data looked at how biologics affect severe asthma in adults. The study included data from 480 patients to compare periods when patients were taking these medications against periods when they were not. The results showed a significant drop in the rate of severe asthma flare-ups for those using biologics.

The research also looked at specific factors that might influence how well the treatment works. Patients with a history of smoking, a history of frequent flare-ups, and higher levels of certain markers like blood eosinophils and nitric oxide showed a stronger reduction in exacerbations. These findings suggest that certain patient profiles may benefit more from these specific treatments.

Because this study included some exclusions based on lung function tests, the results might not apply to everyone with asthma. While the data shows a strong link between biologics and fewer flare-ups, the results are based on a mix of controlled trials and observational data. You should talk to your doctor to see if these specific markers apply to your personal health profile.

What this means for you:

Biologics are linked to fewer severe asthma flare-ups, especially for patients with specific biological markers.

Common questions

How effective are biologics for severe asthma?

The study found that biologics significantly reduced the rates of severe asthma exacerbations. In both clinical trials and real-world data, patients using these medications experienced fewer flare-ups compared to periods when they were not using them.

Who benefits the most from biologic treatments?

The data suggests that certain factors may lead to better results. Patients with a history of frequent exacerbations, a history of smoking, and higher levels of blood eosinophils or nitric oxide showed a significant reduction in flare-ups when using biologics.

Are there any limitations to these findings?

The study notes that some patients were excluded based on lung function tests. This means the results might not apply to everyone with asthma. You should discuss your specific lung function and history with your doctor to see if biologics are right for you.

Study Details

Study typeMeta analysis

Sample sizen = 480

EvidenceLevel 1

PublishedOct 2026

PMID42242757

TrialNCT03373045

View Original Abstract ↓

BACKGROUND: The trade-offs between regulatory preferences, trial success probability, and patient exclusion by eligibility criteria in randomised controlled trials (RCTs) of biologics for severe asthma remain poorly understood. We assessed biologic effectiveness and effect modification by nine RCT-derived criteria in a large real-world cohort of subspecialist-treated patients with severe asthma. METHODS: CHRONICLE was a multicentre, prospective, noninterventional cohort of adults (aged ≥18 years) in the United States of America with severe asthma (ClinicalTrials.gov identifier NCT03373045). We performed a meta-analysis of six RCTs to estimate pooled rate ratios for United States Food and Drug Administration approved biologics and compared with incidence rate ratios (IRRs) from a self-controlled case-series using CHRONICLE data, analysing severe asthma exacerbation rates during biologic-exposed and unexposed periods. Subgroup analyses examined between-group comparisons (inclusion exclusion) across nine RCT-based criteria. FINDINGS: Biologics reduced exacerbation rates in both RCT meta-analysis (rate ratio 0.53, 95% CI 0.47-0.60) and real-world self-controlled case-series of 480 patients from 85 sites (enrolled between 28 February 2018 and 28 October 2024) (IRR 0.43, 95% CI 0.39-0.48). Significant effect modification (ratio of ratios, ratio of IRR (95% CI), with exclusion as the reference) was observed for smoking history (0.50, 0.38-0.66), exacerbation history (0.49, 0.36-0.65), exhaled nitric oxide fraction (0.63, 0.42-0.92), and blood eosinophil count (0.65, 0.51-0.82). No significant differences were observed for COPD, bronchiectasis, or forced expiratory volume in 1 s based criteria, which excluded the most patients in the cohort. INTERPRETATION: Criteria based on elevated type 2 biomarkers, minimal smoking, and exacerbation history enrich trial populations likely to benefit from biologics. Spirometry-based exclusions appear to have limited influence on treatment response, and there is a risk that they unduly restrict generalisability.

Biologics reduce severe asthma exacerbation rates in meta-analysis of 6 RCTs and a case-seriesBiologics Show Significant Reduction in Severe Asthma Exacerbation Rates

How this fits prior evidence

Common questions

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Biologics reduce severe asthma exacerbation rates in meta-analysis of 6 RCTs and a case-seriesBiologics Show Significant Reduction in Severe Asthma Exacerbation Rates

How this fits prior evidence

Common questions

More on Asthma

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties